LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Torin1 | 0.37 | uM | LJP6 | 3 | O16 | 72 | hr | 868 | 1542 | 3486 | 0.4423 | 0.2574 |
MDA-MB-231 | Torin2 | 0.37 | uM | LJP5 | 1 | I22 | 72 | hr | 868 | 1039 | 3486 | 0.2980 | 0.0653 |
MDA-MB-231 | Torin2 | 0.37 | uM | LJP5 | 2 | I22 | 72 | hr | 868 | 1122 | 3486 | 0.3218 | 0.0970 |
MDA-MB-231 | Torin2 | 0.37 | uM | LJP5 | 3 | I22 | 72 | hr | 868 | 1136 | 3486 | 0.3258 | 0.1023 |
MDA-MB-231 | Tozasertib | 0.37 | uM | LJP5 | 1 | B16 | 72 | hr | 868 | 1129 | 3486 | 0.3238 | 0.0996 |
MDA-MB-231 | Tozasertib | 0.37 | uM | LJP5 | 2 | B16 | 72 | hr | 868 | 1070 | 3486 | 0.3069 | 0.0771 |
MDA-MB-231 | Tozasertib | 0.37 | uM | LJP5 | 3 | B16 | 72 | hr | 868 | 1123 | 3486 | 0.3221 | 0.0973 |
MDA-MB-231 | Trametinib | 0.37 | uM | LJP5 | 1 | P22 | 72 | hr | 868 | 1249 | 3486 | 0.3583 | 0.1455 |
MDA-MB-231 | Trametinib | 0.37 | uM | LJP5 | 2 | P22 | 72 | hr | 868 | 1128 | 3486 | 0.3235 | 0.0993 |
MDA-MB-231 | Trametinib | 0.37 | uM | LJP5 | 3 | P22 | 72 | hr | 868 | 1222 | 3486 | 0.3505 | 0.1352 |
MDA-MB-231 | TWS119 | 0.37 | uM | LJP5 | 1 | M04 | 72 | hr | 868 | 3409 | 3486 | 0.9778 | 0.9704 |
MDA-MB-231 | TWS119 | 0.37 | uM | LJP5 | 2 | M04 | 72 | hr | 868 | 3623 | 3486 | 1.0392 | 1.0522 |
MDA-MB-231 | TWS119 | 0.37 | uM | LJP5 | 3 | M04 | 72 | hr | 868 | 3360 | 3486 | 0.9638 | 0.9517 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 1 | C16 | 72 | hr | 868 | 3209 | 3486 | 0.9204 | 0.8941 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 2 | C16 | 72 | hr | 868 | 3289 | 3486 | 0.9434 | 0.9246 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 3 | C16 | 72 | hr | 868 | 3243 | 3486 | 0.9302 | 0.9070 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP5 | 1 | G16 | 72 | hr | 868 | 2291 | 3486 | 0.6571 | 0.5434 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP5 | 2 | G16 | 72 | hr | 868 | 2231 | 3486 | 0.6399 | 0.5205 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP5 | 3 | G16 | 72 | hr | 868 | 2079 | 3486 | 0.5963 | 0.4625 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP6 | 1 | G16 | 72 | hr | 868 | 1818 | 3486 | 0.5215 | 0.3628 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP6 | 2 | G16 | 72 | hr | 868 | 1999 | 3486 | 0.5734 | 0.4319 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP6 | 3 | G16 | 72 | hr | 868 | 1939 | 3486 | 0.5562 | 0.4090 |
MDA-MB-231 | WYE-125132 | 0.37 | uM | LJP6 | 1 | L10 | 72 | hr | 868 | 1758 | 3486 | 0.5043 | 0.3399 |
MDA-MB-231 | WYE-125132 | 0.37 | uM | LJP6 | 2 | L10 | 72 | hr | 868 | 1913 | 3486 | 0.5487 | 0.3991 |
MDA-MB-231 | WYE-125132 | 0.37 | uM | LJP6 | 3 | L10 | 72 | hr | 868 | 1948 | 3486 | 0.5587 | 0.4124 |